These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Tumor Biology Rather Than Surgical Technique Dictates Prognosis in Colorectal Cancer Liver Metastases. Margonis GA; Sasaki K; Kim Y; Samaha M; Buettner S; Amini N; Antoniou E; Pawlik TM J Gastrointest Surg; 2016 Nov; 20(11):1821-1829. PubMed ID: 27384430 [TBL] [Abstract][Full Text] [Related]
31. [Long-term outcomes of patients undergoing hepatectomy for bilateral multiple colorectal liver metastases-a propensity score matching analysis]. Bao Q; Wang K; Wang HW; Jin KM; Xing BC Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Oct; 23(10):976-983. PubMed ID: 33053993 [No Abstract] [Full Text] [Related]
32. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability. Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994 [TBL] [Abstract][Full Text] [Related]
33. Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. Passiglia F; Bronte G; Bazan V; Galvano A; Vincenzi B; Russo A Crit Rev Oncol Hematol; 2016 Mar; 99():150-7. PubMed ID: 26775732 [TBL] [Abstract][Full Text] [Related]
34. Prognostic factors differ according to KRAS mutational status: A classification and regression tree model to define prognostic groups after hepatectomy for colorectal liver metastasis. Moro A; Mehta R; Tsilimigras DI; Sahara K; Paredes AZ; Bagante F; Guglielmi A; Alexandrescu S; Poultsides GA; Sasaki K; Aucejo FN; Pawlik TM Surgery; 2020 Sep; 168(3):497-503. PubMed ID: 32675031 [TBL] [Abstract][Full Text] [Related]
35. Activating KRAS mutation is prognostic only among patients who receive preoperative chemotherapy before resection of colorectal liver metastases. Margonis GA; Kim Y; Sasaki K; Samaha M; Buettner S; Amini N; Pawlik TM J Surg Oncol; 2016 Sep; 114(3):361-7. PubMed ID: 27264476 [TBL] [Abstract][Full Text] [Related]
36. The association of KRAS mutation with primary tumor location and survival in patients undergoing resection of colorectal cancers and synchronous liver metastases. Allievi N; Goffredo P; Utria AF; Pisano M; Poiasina E; Lucianetti A; Zhou P; Hassan I Chin Clin Oncol; 2019 Oct; 8(5):46. PubMed ID: 31500429 [TBL] [Abstract][Full Text] [Related]
37. Salvage treatment for recurrences after first resection of colorectal liver metastases: the impact of histopathological growth patterns. Nierop PMH; Galjart B; Höppener DJ; van der Stok EP; Coebergh van den Braak RRJ; Vermeulen PB; Grünhagen DJ; Verhoef C Clin Exp Metastasis; 2019 Apr; 36(2):109-118. PubMed ID: 30843120 [TBL] [Abstract][Full Text] [Related]
38. RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases. Okuno M; Goumard C; Kopetz S; Vega EA; Joechle K; Mizuno T; Omichi K; Tzeng CD; Chun YS; Vauthey JN; Conrad C Ann Surg Oncol; 2018 Aug; 25(8):2457-2466. PubMed ID: 29786130 [TBL] [Abstract][Full Text] [Related]
39. KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion. Shindoh J; Nishioka Y; Yoshioka R; Sugawara T; Sakamoto Y; Hasegawa K; Hashimoto M; Kokudo N Ann Surg Oncol; 2016 Jun; 23(6):1890-6. PubMed ID: 26786089 [TBL] [Abstract][Full Text] [Related]
40. KRAS Mutation Status Dictates Optimal Surgical Margin Width in Patients Undergoing Resection of Colorectal Liver Metastases. Margonis GA; Sasaki K; Andreatos N; Kim Y; Merath K; Wagner D; Wilson A; Buettner S; Amini N; Antoniou E; Pawlik TM Ann Surg Oncol; 2017 Jan; 24(1):264-271. PubMed ID: 27696170 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]